Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Hold” by Analysts

Cryoport, Inc. (NASDAQ:CYRXGet Free Report) has been given an average recommendation of “Hold” by the eight analysts that are covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $18.25.

A number of equities research analysts have recently weighed in on the stock. B. Riley lowered shares of Cryoport from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $22.00 to $19.00 in a report on Friday, May 3rd. Jefferies Financial Group started coverage on shares of Cryoport in a report on Thursday, April 4th. They issued a “buy” rating and a $21.00 price target on the stock. UBS Group upped their price target on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a report on Friday, March 15th. Stephens reaffirmed an “equal weight” rating and issued a $17.00 price target on shares of Cryoport in a report on Wednesday, March 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price target on shares of Cryoport in a report on Wednesday, May 8th.

View Our Latest Stock Analysis on CYRX

Cryoport Price Performance

Shares of CYRX opened at $11.12 on Wednesday. The firm has a market capitalization of $547.74 million, a PE ratio of -4.50 and a beta of 1.60. The company has a debt-to-equity ratio of 0.86, a current ratio of 10.73 and a quick ratio of 10.22. Cryoport has a 1-year low of $9.00 and a 1-year high of $23.50. The company’s fifty day moving average price is $15.73 and its 200-day moving average price is $15.46.

Cryoport (NASDAQ:CYRXGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). The company had revenue of $54.59 million for the quarter, compared to analysts’ expectations of $58.78 million. Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. Cryoport’s quarterly revenue was down 13.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.16) earnings per share. On average, equities research analysts predict that Cryoport will post -1.37 EPS for the current year.

Insider Transactions at Cryoport

In other news, Director Richard J. Berman sold 8,105 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the sale, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $1,341,000. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Richard J. Berman sold 8,105 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total transaction of $108,688.05. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at approximately $1,341,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Edward J. Zecchini sold 3,443 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $13.37, for a total transaction of $46,032.91. Following the transaction, the insider now owns 60,051 shares of the company’s stock, valued at approximately $802,881.87. The disclosure for this sale can be found here. Insiders have sold a total of 85,488 shares of company stock valued at $1,302,259 in the last ninety days. 10.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Cryoport by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 3,559,092 shares of the company’s stock worth $48,795,000 after purchasing an additional 74,037 shares during the last quarter. Cadian Capital Management LP raised its position in shares of Cryoport by 30.4% during the 4th quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock worth $53,659,000 after purchasing an additional 807,340 shares during the last quarter. Invesco Ltd. raised its holdings in Cryoport by 17.9% in the 3rd quarter. Invesco Ltd. now owns 2,062,481 shares of the company’s stock valued at $28,277,000 after acquiring an additional 313,853 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Cryoport by 46.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock valued at $30,870,000 after acquiring an additional 636,395 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Cryoport by 29.9% in the 4th quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock valued at $25,446,000 after acquiring an additional 378,340 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Company Profile

(Get Free Report

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Further Reading

Analyst Recommendations for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.